Sugita, Mayumi
Yamazaki, Takahiro
Alhomoud, Mohammad
Martinet, Jérémie
Latouche, Jean-Baptiste
Golden, Encouse
Boyer, Olivier
Van Besien, Koen
Formenti, Silvia C.
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Guzman, Monica L. http://orcid.org/0000-0002-9262-8246
Article History
Received: 30 March 2023
Revised: 12 April 2023
Accepted: 21 April 2023
First Online: 4 May 2023
Competing interests
: OB has been holding research contracts with Argenx and UCB, and has received consulting/advisory honoraria from Argenx, UCB, CSL Behring, BMS, OGD2 pharma and Egle therapeutics. SCF has been holding research contracts with Merck, Varian, Bristol Myers Squibb, Celldex, Regeneron, Eisai, and Eli-Lilly, and has received consulting/advisory honoraria from Bayer, Bristol Myers Squibb, Varian, Elekta, Regeneron, Eisai, AstraZeneca, MedImmune, Merck US, EMD Serono, Accuray, Boehringer Ingelheim, Roche, Genentech, AstraZeneca, View Ray and Nanobiotix. LG has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Imvax, Inzen, EduCom, Sotio, Promontory, Noxopharm and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. MLG holds research contracts and does consulting with Bridge Medicines, stock options for SeqRX, has done consulting for Janssen. All other authors declare no competing interests.